NCT06799065
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06799065
Title First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Accent Therapeutics
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Colorado Denver RECRUITING Aurora Colorado 80045 United States Details
Florida Cancer Specialists RECRUITING Sarasota Florida 34232 United States Details
Karmanos Cancer Institute RECRUITING Detroit Michigan 48201 United States Details
Washington University RECRUITING St Louis Missouri 63130 United States Details
University of Nebraska Medical Center RECRUITING Omaha Nebraska 68198 United States Details
NYU Longone Health (Long Island) RECRUITING Long Island City New York 11501 United States Details
NYU Longone Health (Manhattan) RECRUITING Manhattan New York 10012 United States Details
SCRI Oncology Partners RECRUITING Nashville Tennessee 37203 United States Details
MD Anderson Cancer Center RECRUITING Houston Texas 77030 United States Details
NEXT Oncology RECRUITING San Antonio Texas 78229 United States Details
NEXT Virginia RECRUITING Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field